Chernyshov, P. V., Finlay, Andrew ![]() |
![]() |
PDF
- Accepted Post-Print Version
Download (294kB) |
Abstract
The European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on Quality of Life (QoL) and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa (ARHS) do not recommend the use of any generic instrument as a single method of Health Related (HR) QoL assessment in rosacea, except when comparing quimp (quality of life impairment) in rosacea patients with that in other non-dermatologic skin diseases and/or healthy controls. The EADV TFs on QoL and Patient-Oriented Outcomes and ARHS recommend the use of the dermatology-specific HRQoL instrument the Dermatology Life Quality Index (DLQI) and the rosacea-specific HRQoL instrument RosaQoL in rosacea patients. The DLQI minimal clinically important difference may be used as a marker of clinical efficacy of the treatment and DLQI score banding of 0 or 1 corresponding to no effect on patients' HRQoL could be an important treatment goal. This information may be added to consensuses and guidelines for rosacea.
Item Type: | Article |
---|---|
Date Type: | Published Online |
Status: | Published |
Schools: | Medicine |
Publisher: | Wiley |
ISSN: | 0926-9959 |
Date of First Compliant Deposit: | 23 March 2023 |
Date of Acceptance: | 16 January 2023 |
Last Modified: | 11 Nov 2024 21:15 |
URI: | https://orca.cardiff.ac.uk/id/eprint/157902 |
Actions (repository staff only)
![]() |
Edit Item |